Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GreeceBack to Greece

Clinical trials in Piraeus – page 80

1 004 clinical trials in Piraeus, Greece across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Piraeus at a glance
1 004
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 004 trials in Piraeus

Open in trial search

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with Low PD-L1 Levels

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Non-small cell lung cancer stage III

Not recruiting

Study of Nivolumab and Ipilimumab for Patients with Stage 3 Non-Small Cell Lung Cancer Not Suitable for Surgery

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol Myers Squibb International Corporation

Dermatomyositis+1

Not recruiting

Study on the Effects of Enpatoran for Patients with Dermatomyositis and Polymyositis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran
  • Sponsor:Merck Healthcare KGaA

Heart failure with reduced ejection fraction

Not recruiting

Study on Vericiguat for Adults with Chronic Heart Failure with Reduced Ejection Fraction

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Vericiguat
  • Sponsor:Merck Sharp & Dohme LLC

Sepsis

Not recruiting

Study on Avibactam and Drug Combination for Treating Severe Infections in Patients

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Anidulafungin
  • Sponsor:Hellenic Institute For The Study Of Sepsis

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Zilovertamab Vedotin for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Zilovertamab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Diffuse large B-cell lymphoma

Not recruiting

Study of Zilovertamab Vedotin with Drug Combination for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Merck Sharp & Dohme LLC

COVID-19

Not recruiting

Study on the Effects of S-217622 for Adults Hospitalized with COVID-19

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Sponsor:University Of Minnesota

Breast cancer

Not recruiting

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Pfizer Inc.

Malignant melanoma

Not recruiting

Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma

Registered drug
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Myelofibrosis+2

Not recruiting

Continued Treatment Study for Patients with Myelofibrosis, Post-Lung Transplant BOS, or Chronic Graft-Versus-Host Disease Using Itacitinib

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Itacitinib
  • Sponsor:Incyte Corp.

Other cities in Greece

The busiest research cities in the country

All 45 cities in Greece

Clinical research in Piraeus

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on various cancer treatments, particularly in non-small cell lung cancer and novel therapeutic combinations. Studies include investigations of targeted therapies and immunotherapy approaches.

  • Lung Cancer Therapies
  • Melanoma Treatments
  • Renal Cell Carcinoma

Innovative research combining standard treatments with new therapeutic agents to improve patient outcomes.

02 Cardiovascular Studies

Research initiatives targeting heart failure prevention and stroke prevention in patients with atrial fibrillation. Studies evaluate new therapeutic approaches for managing cardiovascular risks.

  • Heart Failure Prevention
  • Stroke Prevention
  • Hypertension Management

Trials focusing on both preventive measures and treatment of established cardiovascular conditions.

03 Hematology Research

Clinical investigations in multiple myeloma and related blood disorders, exploring combination therapies and novel treatment approaches for patients with various blood-related conditions.

  • Multiple Myeloma
  • Plasma Cell Leukemia
  • Blood Disorders

Studies examining innovative therapeutic combinations for improved patient outcomes.

04 Inflammatory Conditions

Research focusing on treating Crohn's Disease and other inflammatory conditions, evaluating new therapeutic options and combination treatments for better disease management.

  • Gastrointestinal Disorders
  • Autoimmune Conditions
  • Novel Therapies

Studies aimed at improving treatment outcomes in chronic inflammatory diseases.

Back to GreeceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.